ACTRN12610000011088
已完成
3 期
To test the hypothesis that ischaemic stroke patients selected with significant penumbral mismatch at 4.5 - 9 hours post onset of stroke will have improved clinical outcomes when given intravenous Tissue Plasminogen Activator (tPA) compared to placebo
概览
- 阶段
- 3 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Stroke
- 发起方
- The Florey Institute of Neuroscience and Mental health
- 入组人数
- 225
- 状态
- 已完成
- 最后更新
- 6年前
概览
简要总结
Among the patients in this trial who had ischemic stroke and salvageable brain tissue, the use of alteplase between 4.5 and 9.0 hours after stroke onset or at the time the patient awoke with stroke symptoms resulted in a higher percentage of patients with no or minor neurologic deficits than the use of placebo. There were more cases of symptomatic cerebral hemorrhage in the alteplase group than in the placebo group.
研究者
入排标准
入选标准
- •1\. Patients presenting with hemispheric acute ischaemic stroke 2\. Patient, family member or legally responsible person depending on local ethics requirements has given informed consent 3\. Patient’s age is \>\=18 years 4\. Treatment onset can commence within 4\.5 – 9 hours after stroke onset according to registered product information, or between 3 – 9 hours according to locally accepted guidelines 5\. Patients who wake with stroke may be included if neurological and other exclusion criteria are satisfied. These ‘wake up’ strokes are defined as having no symptoms at sleep onset, but stroke symptoms on waking. The time of stroke onset is to be taken as the mid\-point between sleep onset (or last known to be normal) and time of waking. The maximum time window for randomisation is then 9 hours from the mid\-point as described. 6\. NIHSS score of \>\=4 \- 26 with clinical signs of hemispheric infarction. 7\. Penumbral imaging\*\* –Using a Tmax\>6 second delay, a perfusion (PWI) volume to diffusion (DWI) volume ratio of \> 1\.2, a DWI lesion \<\=70ml and PWI\-DWI difference of \>10ml \*\* Patients may be consented before or after penumbral screening depending upon local practice. The entire cohort of patients consented onto the study will be followed up with clinical assessments and biomarker studies regardless of eligibility for randomisation to treatment based on penumbral mismatch criteria.
排除标准
- •1\. Intracranial haemorrhage (ICH) identified by computed tomography (CT) or Magnetic Resonance Imaging (MRI) 2\. Rapidly improving symptoms, particularly if in the judgment of the managing clinician that the improvement is likely to result in the patient having an NIHSS score of \< 4 at randomization 3\. Pre\-stroke MRS score of \>\=2 (indicating previous disability) 4\. Contra indication to imaging with MR with contrast agents 5\. Infarct core \>1/3 Middle Cerebral Artery (MCA) territory qualitatively 6\. Participation in any investigational study in the previous 30 days 7\. Any terminal illness such that patient would not be expected to survive more than 1 year 8\. Any condition that could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study (this applies to patients with severe microangiopathy such as haemolytic uremic syndrome or thrombotic thrombocytopenic purpura). The judgment is left to the discretion of the Investigator. 9\. Pregnant women (clinically evident) 10\. Previous stroke within last three months 11\. Recent past history or clinical presentation of ICH, subarachnoid haemorrhage (SAH), arterio\-venous (AV) malformation, aneurysm, or cerebral neoplasm. At the discretion of each Investigator. 12\. Current use of oral anticoagulants and a prolonged International Normalized Ratio (INR) \> 1\.6 13\. Use of heparin, except for low dose subcutaneous heparin, in the previous 48 hours and a prolonged activated partial thromboplastin time exceeding the upper limit of the local laboratory normal range. 14\. Use of glycoprotein IIb \- IIIa inhibitors within the past 72 hours. Use of single or dual agent oral platelet inhibitors (clopidogrel and/or low\-dose aspirin) prior to study entry is permitted. 15\. Clinically significant hypoglycaemia. 16\. Uncontrolled hypertension defined by a blood pressure \> 185 mmHg systolic or \>110 mmHg diastolic on at least 2 separate occasions at least 10 minutes apart, or requiring aggressive treatment to reduce the blood pressure to within these limits. The definition of aggressive treatment” is left to the discretion of the responsible Investigator. 17\. Hereditary or acquired haemorrhagic diathesis 18\. Gastrointestinal or urinary bleeding within the preceding 21 days 19\. Major surgery within the preceding 14 days which poses risk in the opinion of the investigator. 20\. Exposure to a thrombolytic agent within the previous 72 hours
结局指标
主要结局
未指定
相似试验
终止
不适用
Pragmatic Ischaemic Stroke Thrombectomy EvaluationAcute Ischaemic StrokeNCT01745692NHS Greater Glasgow and Clyde65
已完成
3 期
A RCT to Establish the Effectiveness of Intermittent Pneumatic Compression to Prevent Post Stroke DVTStrokeNCT00789542University of Edinburgh2,876
Unknown
3 期
The STem Cell Application Researches and Trials In NeuroloGy-2 (STARTING-2) StudyStroke, IschemicNCT01716481Samsung Medical Center60
已完成
2 期
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)StrokeBrain InfarctionNCT01977456Arthur Pancioli27
已完成
不适用
Confounding Factors in the Detection of Intracranial Hemorrhage With the InfrascannerIschemic StrokeBrain TumorBrain SurgeryIntracranial HemorrhageHeadacheHead TraumaNCT02809651Ziekenhuis Oost-Limburg89